Hosmer Allen Johnson Professor of Pathology Professor, Pathology (Experimental Pathology)
Bio
A better understating of the molecular mechanisms by which breast cancer develops, progresses and spreads into distance organs is urgently needed. Over the last decade, our laboratory is among the first who identified an enzyme called USP22 as an oncogene for a variety of solid tumors including breast cancer. Preliminary studies in the currently application discovered that USP22 promotes breast cancer cell expression of surface molecules including PD-L1, CD73 and Integrins, which are involved in suppressing the antitumor immune response and facilitating tumor cell spreading into distance organs. We developed a USP22 inhibitor that can potentially kill breast cancer cells and enhance anti-tumor immunity. This study is to study how USP22 promotes breast cancer cell surface PD-L1, CD73 and Integrin expression and to evaluate the pre-clinical efficacy of USP22 inhibitor in breast cancer treatment.
Deyu Fang, PhD
Northwestern University, Feinberg School of Medicine
Past
Senior Investigator
Ann Marie Flores, PT, PhD
A Pilot Test of the Breast Cancer Pre-habilitation and Prospective Surveillance to Prevent, Detect, and Optimize Physical and Functional Recovery (B-PREPeD)
Past
Senior Investigator
Dr. Jun Huang
Developing a Combinatorial mRNA Immunotherapy for Breast Cancer
Why your gift matters
Your gift helps researchers test bold ideas, generate critical data, and take the first steps toward the next major advancement in breast cancer treatment and care.Together, we can accelerate discoveries that save lives.
